Disc Medicine (IRON) Other Gross PP&E Adjustments (2020 - 2026)
Disc Medicine (IRON) reported Other Gross PP&E Adjustments of -$2.4 million for Q1 2026, up 25.77% year-over-year from -$1.9 million in Q1 2025, and up 26.56% on a QoQ basis from -$3.3 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$2.4 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 25.77% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (up 25.77% YoY) and the FY2025 annual result came in at -$3.3 million, up 24.94% from the prior year.
- Other Gross PP&E Adjustments grew to -$2.4 million in Q1 2026 per IRON's latest filing, from -$3.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$87000.0 in Q3 2022 and bottomed at -$4.4 million in Q4 2024.
- The 5-year median for Other Gross PP&E Adjustments is -$2.2 million (2024), against an average of -$2.0 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments surged 76.55%; it then tumbled 2306.9% in 2023.
- Tracing IRON's Other Gross PP&E Adjustments over 5 years: stood at -$1.9 million in 2022, then sank by 58.45% to -$2.9 million in 2023, then sank by 50.36% to -$4.4 million in 2024, then rose by 24.94% to -$3.3 million in 2025, then advanced by 26.56% to -$2.4 million in 2026.
- Per Business Quant, the three latest IRON Other Gross PP&E Adjustments figures stand at -$2.4 million (Q1 2026), -$3.3 million (Q4 2025), and -$2.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -2.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.43 Mn |
| Mar 31, 2026 | -2.43 Mn |
| Dec 31, 2025 | -3.31 Mn |
| Dec 31, 2025 | -3.31 Mn |
| Sep 30, 2025 | -2.59 Mn |
| Sep 30, 2025 | -2.59 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Jun 30, 2025 | -2.54 Mn |
| Mar 31, 2025 | -3.28 Mn |
| Mar 31, 2025 | -3.28 Mn |
| Dec 31, 2024 | -4.41 Mn |
| Dec 31, 2024 | -4.41 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -2.17 Mn |
| Jun 30, 2024 | -2.17 Mn |
| Mar 31, 2024 | -2.25 Mn |
| Mar 31, 2024 | -2.25 Mn |
| Dec 31, 2023 | -2.93 Mn |
| Dec 31, 2023 | -2.93 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Sep 30, 2023 | -2.09 Mn |
| Jun 30, 2023 | -210,000.00 |
| Jun 30, 2023 | -210,000.00 |
| Mar 31, 2023 | -1.55 Mn |
| Mar 31, 2023 | -1.55 Mn |
| Dec 31, 2022 | -1.85 Mn |
| Dec 31, 2022 | -1.85 Mn |
| Sep 30, 2022 | -87,000.00 |
| Sep 30, 2022 | -87,000.00 |
| Jun 30, 2022 | -186,000.00 |
| Jun 30, 2022 | -186,000.00 |
| Mar 31, 2022 | -565,000.00 |
| Mar 31, 2022 | -565,000.00 |
| Dec 31, 2021 | -2.15 Mn |
| Dec 31, 2021 | -2.15 Mn |
| Sep 30, 2021 | -371,000.00 |
| Sep 30, 2021 | -371,000.00 |
| Jun 30, 2021 | -388,000.00 |
| Jun 30, 2021 | -388,000.00 |
| Mar 31, 2021 | -577,000.00 |
| Mar 31, 2021 | -577,000.00 |
| Dec 31, 2020 | 264,000.00 |
| Dec 31, 2020 | 264,000.00 |